A systematic review of the effectiveness of adalimumab

46. Young A, Dixey J, Cox N, Davies P, Devlin J,
Emery P. How does disability in early rheumatoid
arthritis (RA) affect patients and their lives?
Results of 5 years follow-up in 732 patients from
the Early RA Study (ERAS). Rheumatology 2000;
39:603–11.
47. Uhlig T, Smedstad L, Vaglum P, Moum T, Gerard N,
Kvien T. The course of rheumatoid arthritis and
predictors of psychological, physical and
radiographic outcome after 5 years of follow-up.
Rheumatology 2000;39:732–41.
48. Barrett EM, Scott DGI, Wiles N, Symmons D.
The impact of rheumatoid arthritis on
employment status in the early years of disease:
a UK community-based study. Rheumatology 2000;
39:1403–9.
49. Chorus AMJ, Miedem HS, Wevers CJ, van der
Linden S. Labour force participation among
patients with rheumatoid arthritis. Ann Rheum Dis
2000;59:549–54.
50. Goodson N, Wiles N, Lunt M, Barrett EM,
Silman A, Symmons DPM. Mortality in early
inflammatory polyarthritis. Cardiovascular disease
is increased in seropositive patients. Arthritis Rheum
2002;46:2010–19.
51. Boers M, Dijkmans B, Gabriel S, Maradit-
Kremers H, O’Dell J, Pincus T. Making an impact
on mortality in rheumatoid arthritis. Targeting
cardiovascular disease. Arthritis Rheum 2004;
50:1734–9.
52. Navarro-Cano G, del Rincon I, Pogosian S,
Roldan JF, Escalante A. Association of mortality
with disease severity in rheumatoid arthritis,
independent of comorbidity. Arthritis Rheum 2003;
48:2425–33.
53. Ward MM. Recent improvements in survival in
patients with rheumatoid arthritis: better outcomes
or different study designs? Arthritis Rheum 2001;
44:1467–9.
54. Gabriel SE, Crowson CS, Kremers HM, Doran MF,
Turesson C, O’Fallon WM, et al. Survival in
rheumatoid arthritis: a population-based analysis
of trends over 40 years. Arthritis Rheum 2003;
48:54–8.
55. Hallert E, Husberg M, Jonsson D, Skogh T.
Rheumatoid arthritis is already expensive during
the first year of the disease (the Swedish TIRA
project). Rheumatology 2004;43:1374–82.
56. Brouwer WB, van Exel NJ, Van de Berg B,
Dinant HJ, Koopmanschap MA. Burden of
caregiving: evidence of objective burden,
subjective burden, and quality of life impacts on
informal caregivers of patients with rheumatoid
arthritis. Arthritis Rheum 2004;51:570–7.
57. Michaud K, Messer J, Choi HK, Wolfe F. Direct
medical costs and their predictors in patients with
rheumatoid arthritis: a three-year study of 7,257
patients. Arthritis Rheum 2003;48:2750–62.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
58. Puolakka K, Kautiainen H, Mottonen T,
Hannonen P, Korpela M, Julkunen H, et al. Impact
of initial aggressive drug treatment with a
combination of disease-modifying antirheumatic
drugs on the development of work disability in
early rheumatoid arthritis: a five-year randomized
follow-up trial. Arthritis Rheum 2004;50:55–62.
59. Young A, Dixey J, Kulinskay E, Cox N, Davies P,
Devlin J, et al. Which patients stop working
because of rheumatoid arthritis? Results of five
years’ follow up in 732 patients from Early RA
Study (ERAS). Ann Rheum Dis 2002;6:335–40.
60. Audit Commission. Managing the financial
implications of NICE guidance ISBN 186240 513 1.
London: Audit Commission; 2005.
61. Arthritis and Musculoskeletal Alliance. Standards
of care for people with inflammatory arthritis.
URL: http://www.arma.uk.net/pdfs/ia.pdf. Accessed
22 May 2005.
62. Griffiths I, Silman A, Symmons D, Scott DGI. BSR
Biologics Registry. Rheumatology 2004;43:1463–4.
63. Knights SE, Averns H. The influence of resource
limitation on the use of biologic agents in South
West England. Rheumatology 2004; 43(Suppl 2):
ii76.
64. British Society for Rheumatology and the
Musculoskeletal Alliance. Access to anti-TNF
therapies for adults with inflammatory arthritis.
URL: http://www.rheumatology.org.uk/media/
pressreleases/pressreleasebsrarmasurvey. Accessed
13 June 2005.
65. Somerville MF, Brooksby A, Gaffney K, Scott DGI.
Anti-TNF: patients, politics and practicalities of
access to treatment during the last four years.
Rheumatology 2004;43(Suppl 2):ii39–40.
66. Abbott Laboratories. Press release. URL:
http://abbott.com/news/press_release.cfm?id=867.
Accessed 14 June 2005.
67. European Medicines Agency. Committee for
medicinal products for human use postauthorisation
summary of option for Humira.
URL: http://www.emea.eu.int/pdfs/human/opinion/
20715105en.pdf. Accessed 18 August 2005.
68. Mahmood I, Green MD. Center for Drug
Evaluation and Research and Center for Biologics
Evaluation and Research. Application No.
125057/0. Clinical pharmacology and
biopharmaceutics review(s). URL:
http://www.fda.gov/cder/biologics/review/
BLA125057_S000_HUMIRA_BIOPHARMR.pdf.
Accessed 14 June 2005.
69. Abbott Laboratories. Humira 40 mg solution for
injection in pre-filled syringe. Summary of product
characteristics. URL: http://emc.medicines.org.uk/
emc/industry/default.asp?page=displaydoc.asp&
documentid=13111. Accessed 14 June 2005.
129